Is it safe to co‑administer diltiazem with enzalutamide, and what dose adjustments or monitoring are recommended?

Co-administration of Diltiazem with Enzalutamide is NOT Safe and Should Be Avoided

Avoid combining diltiazem with enzalutamide due to a clinically significant drug-drug interaction that can result in loss of therapeutic efficacy of diltiazem, potentially leading to uncontrolled tachycardia and heart failure.

The Critical Drug Interaction

Enzalutamide is a strong CYP3A4 inducer 1, while diltiazem is a major CYP3A4 substrate 2, 3. When co-administered, enzalutamide dramatically reduces diltiazem plasma concentrations to potentially subtherapeutic levels through enzyme induction 3.

Clinical Evidence of Harm

A recent case report 4 documented a patient on stable diltiazem for atrial fibrillation rate control who:

• Lost rate control after starting enzalutamide for prostate cancer
• Developed persistent tachycardia
• Suffered tachycardia-induced cardiomyopathy with left ventricular ejection fraction dropping from 52% to <15%
• Required hospitalization and alternative rate control therapy

This represents a life-threatening complication directly attributable to this drug interaction.

FDA Labeling Guidance

The diltiazem FDA label explicitly states: "Coadministration of diltiazem with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered" 3. While this specifically mentions rifampin, enzalutamide is classified as a strong CYP3A4 inducer with similar or greater induction potential 1.

Recommended Management Strategy

If Patient is Already on Diltiazem:

1. Switch to a non-CYP3A4 substrate alternative BEFORE starting enzalutamide:

   • Beta-blockers (metoprolol, atenolol, bisoprolol) - preferred alternatives for rate control 2, 5
   • These are not significantly affected by CYP3A4 induction
   • The case report patient successfully achieved rate control with metoprolol after the interaction 4

2. Monitor closely during transition:

   • Check heart rate and blood pressure
   • Assess for symptoms of inadequate rate control
   • ECG monitoring if indicated

If Patient is Already on Enzalutamide:

1. Do NOT add diltiazem - it will likely be ineffective
2. Choose alternative rate control agents:
   • Beta-blockers (first-line alternative)
   • Digoxin (though less effective for exercise rate control) 6

For Atrial Fibrillation Rate Control Specifically:

Beta-blockers are the preferred alternative 2, 5:

• Metoprolol: 2.5-5 mg IV bolus or 25-200 mg PO daily
• Atenolol: 5 mg IV or 25-100 mg PO daily
• Bisoprolol: 2.5-10 mg PO daily

These provide effective AV nodal blockade without the CYP3A4 interaction liability.

Critical Pitfalls to Avoid

1. Do not simply increase diltiazem dose - enzalutamide's strong induction effect makes dose escalation unpredictable and potentially dangerous
2. Do not assume the interaction is theoretical - the case report 4 demonstrates real-world clinical harm including heart failure
3. Do not overlook this interaction during medication reconciliation - drug interaction databases flag this combination, but clinical awareness is essential 7
4. Avoid verapamil as well - it shares the same CYP3A4 substrate profile as diltiazem 2, 8

Additional Considerations

• Enzalutamide has a long half-life and its induction effects persist for weeks after discontinuation 1
• The interaction affects all formulations of diltiazem (immediate-release, extended-release, IV) 3
• Patients with prostate cancer on enzalutamide often have multiple comorbidities requiring polypharmacy, making systematic drug interaction screening essential 7

The evidence strongly supports avoiding this combination entirely and proactively switching to beta-blocker therapy for rate control in patients requiring enzalutamide 4, 3, 1.